Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Ital ...

Announce initial clinical data from Cohort 1 in the Phase 1/2 trial of PM359 for p47 phox CGD in 2025. The initial readout ...

R&D Expenses: Research and development expenses for the quarter ended March 31, 2025, were $10.1 million, compared to $9.7 million for the quarter ended March 31, 2024. The increase in R&D expenses ...

Cocaine-induced leukoencephalopathy is a rare neurological condition usually associated with substances used to adulterate ...

ongoing clinical updates anticipated throughout 2025 - Received regulatory clearance of IND from the U.S. FDA to expand ELIMINATE-B trial and CTA approved by MHRA for study expansion into the UK.

WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, ...

Shanghai Electric (SEHK:2727, SSE:601727) once again impresses visitors at  this year's Intersolar Europe, the world's leading exhibition for the solar industry, held in Munich from May 7-9. The ...

The decision by Durbin, who is in his fifth Senate term and is the chamber’s No. 2 Democrat, will set off a flurry of activity among a scrum of would-be ...

Enrollment and dosing underway in Phase 3 clinical trial (the“MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML </p ...

Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACL ...

Regional trends driving innovation and demand across key veterinary sectors.” — Sabyasachi Ghosh, Principal Consultant.